Higgins E A, Siminovitch K A, Zhuang D L, Brockhausen I, Dennis J W
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
J Biol Chem. 1991 Apr 5;266(10):6280-90.
The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency affecting B lymphocytes, T lymphocytes, and platelets. Previous studies on lymphocytes from WAS patients have revealed that leu-kosialin (CD43), a cell-surface glycoprotein bearing approximately 90 O-linked oligosaccharide chains, shows an aberrant electrophoretic mobility. To determine whether this finding reflects a different pattern of O-linked glycosylation in WAS cells, we have compared healthy individuals and WAS patients with respect to glycosyltransferase activities in T lymphocytes, platelets, and Epstein-Barr virus (EBV)-immortalized B cell lines. Stimulation of peripheral T cells from normal individuals in vitro with anti-CD3 antibodies and interleukin-2 was associated with a 3-fold increase in UDP-GlcNAc:Gal beta 3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase (core 2 GlcNAc-T) from 0.8 to 2.2 nmol/mg/h. In contrast, peripheral T lymphocytes from WAS patients showed an inversion of this phenotype with high core 2 GlcNAc-T activity in unstimulated cells (2.3 nmol/mg/h) and a 2-3-fold decrease in activity following stimulation. Core 2 GlcNAc-T activity was also three times higher in platelets from WAS patients than in normal platelets. Glycosyltransferase activities were measured in immortalized B cell lines established from WAS and normal subjects by infection with EBV. Core 2 GlcNAc-T was less than 0.4 nmol/mg/h in WAS EBV-B cell lines compared to 2.4 nmol/mg/h in EBV-B cell lines from healthy individuals, In contrast, CMP-SA:SA alpha 2-3Gal beta 1-3GalNAc-R (where SA represents sialyl (sialic acid to GalNAc) alpha 6-sialyltransferase II activity was 2.0 nmol/mg/h in the WAS EBV-B cell and less than .01 nmol/mg/h in EBV-B cell lines derived from normal subjects. Eleven other glycosyltransferase activities were measured and found to be similar in EBV-B cell lines from WAS and normal individuals. Polylactosamine sequences were much reduced in the O-linked oligosaccharides of CD43 from WAS EBV-B cells consistent with decreased core 2 GlcNAc-T activity and expression of core 1 oligosaccharides in the cells. In conclusion, B cells, T cells, and platelets in WAS patients show abnormal expression of two developmentally regulated glycosyltransferases, consistent with the idea that the WAS immunodeficiency is due to a failure of normal lymphocyte maturation.
威斯科特-奥尔德里奇综合征(WAS)是一种X连锁隐性免疫缺陷病,会影响B淋巴细胞、T淋巴细胞和血小板。此前对WAS患者淋巴细胞的研究表明,白细胞唾液酸蛋白(CD43),一种带有约90条O-连接寡糖链的细胞表面糖蛋白,显示出异常的电泳迁移率。为了确定这一发现是否反映了WAS细胞中O-连接糖基化的不同模式,我们比较了健康个体和WAS患者在T淋巴细胞、血小板以及爱泼斯坦-巴尔病毒(EBV)永生化B细胞系中的糖基转移酶活性。用抗CD3抗体和白细胞介素-2在体外刺激正常个体的外周T细胞,会使UDP-GlcNAc:Galβ3GalNAc-R(GlcNAc到GalNAc)β6-N-乙酰葡糖胺转移酶(核心2 GlcNAc-T)的活性从0.8 nmol/mg/h增加3倍至2.2 nmol/mg/h。相比之下,WAS患者的外周T淋巴细胞表现出这种表型的反转,未刺激细胞中的核心2 GlcNAc-T活性较高(2.3 nmol/mg/h),刺激后活性降低2至3倍。WAS患者血小板中的核心2 GlcNAc-T活性也比正常血小板高3倍。通过感染EBV在WAS患者和正常受试者中建立的永生化B细胞系中测量了糖基转移酶活性。WAS EBV-B细胞系中的核心2 GlcNAc-T小于0.4 nmol/mg/h,而健康个体的EBV-B细胞系中的该活性为2.4 nmol/mg/h。相比之下,CMP-SA:SAα2-3Galβ1-3GalNAc-R(其中SA代表唾液酸(唾液酸到GalNAc)α6-唾液酸转移酶II)活性在WAS EBV-B细胞中为2.0 nmol/mg/h,而在来自正常受试者的EBV-B细胞系中小于0.01 nmol/mg/h。还测量了其他11种糖基转移酶活性,发现WAS患者和正常个体的EBV-B细胞系中的这些活性相似。WAS EBV-B细胞中CD43的O-连接寡糖中的聚乳糖胺序列大大减少,这与细胞中核心2 GlcNAc-T活性降低和核心1寡糖的表达一致。总之,WAS患者的B细胞、T细胞和血小板显示出两种发育调节的糖基转移酶的异常表达,这与WAS免疫缺陷是由于正常淋巴细胞成熟失败的观点一致。